Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024

September 9, 2024

Antennova to present ATN-037 data at ESMO Congress 2024, showing 43.8% DCR in monotherapy and 65.0% DCR in combination therapy.

Highlighted Terms

solid tumors non-small cell lung cancer Merck & Co., Inc.NSCLC Antennova Merck Sharp & Dohme LLC melanoma pembrolizumab KEYTRUDA European Society of Medical Oncology ATN-037 U.S. Food and Drug Administration

Related News

morningstar.com

Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024

Antennova to present ATN-037 data at ESMO Congress 2024, showing 43.8% DCR in monotherapy and 65.0% DCR in combination therapy.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy